MedPath

ARIXTRA

These highlights do not include all the information needed to use ARIXTRA safely and effectively. See full prescribing information for ARIXTRA.ARIXTRA (fondaparinux sodium) Solution for subcutaneous injection Initial U.S. Approval: 2001

Approved
Approval ID

ec235119-cb58-4939-942c-11d3923d289f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 23, 2012

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

fondaparinux sodium

PRODUCT DETAILS

NDC Product Code54868-5652
Application NumberNDA021345
Marketing CategoryC73594
Route of AdministrationSUBCUTANEOUS
Effective DateJanuary 23, 2012
Generic Namefondaparinux sodium

INGREDIENTS (3)

FONDAPARINUX SODIUMActive
Quantity: 5 mg in 0.4 mL
Code: X0Q6N9USOZ
Classification: ACTIB
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

fondaparinux sodium

PRODUCT DETAILS

NDC Product Code54868-5501
Application NumberNDA021345
Marketing CategoryC73594
Route of AdministrationSUBCUTANEOUS
Effective DateJanuary 23, 2012
Generic Namefondaparinux sodium

INGREDIENTS (3)

FONDAPARINUX SODIUMActive
Quantity: 7.5 mg in 0.6 mL
Code: X0Q6N9USOZ
Classification: ACTIB
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ARIXTRA - FDA Drug Approval Details